Antibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma

Antibody-based immunotherapeutic agents have emerged as important treatment options for non-Hodgkin lymphoma. Recent data suggest that use of these agents not only induces high response rates but also results in improved survival when combined with conventional chemotherapy in patients with non-Hodgkin lymphoma. As a result, antibody-based immunotherapy has changed lymphoma therapy considerably and dramatically impacted the management of patients with non-Hodgkin lymphoma. Several unmodified and radiolabeled antibodies, as well as antibody-drug conjugates, have been approved by the United States Food and Drug Administration (FDA) for treatment of non-Hodgkin lymphoma. Also, more promising antibodies that target other epitopes are being developed in preclinical and clinical studies. This review presents the latest information on antibody-based innmunotherapeutic agents for treatment of non-Hodgkin lymphoma in various clinical settings and discusses current clinical and laboratory guidelines for the use of antibodies for treatment of different subtypes of non-Hodgkin lymphoma.